Analysts expect Voyager Therapeutics, Inc. (NASDAQ:VYGR) to report $-0.73 EPS on March, 21.They anticipate $0.16 EPS change or 28.07% from last quarter’s $-0.57 EPS. After having $-0.89 EPS previously, Voyager Therapeutics, Inc.’s analysts see -17.98% EPS growth. The stock increased 0.99% or $0.19 during the last trading session, reaching $19.36. About 169,959 shares traded. Voyager Therapeutics, Inc. (NASDAQ:VYGR) has declined 18.89% since February 17, 2017 and is downtrending. It has underperformed by 35.59% the S&P500.
Klondex Mines Limited (NYSEAMERICAN:KLDX) had an increase of 7.38% in short interest. KLDX’s SI was 17.98M shares in February as released by FINRA. Its up 7.38% from 16.75 million shares previously. With 1.11 million avg volume, 16 days are for Klondex Mines Limited (NYSEAMERICAN:KLDX)’s short sellers to cover KLDX’s short positions. The SI to Klondex Mines Limited’s float is 10.35%. The stock decreased 1.90% or $0.03 during the last trading session, reaching $1.55. About 731,830 shares traded. Klondex Mines Ltd. (NYSEAMERICAN:KLDX) has declined 5.13% since February 17, 2017 and is downtrending. It has underperformed by 21.83% the S&P500.
Klondex Mines Ltd., together with its subsidiaries, acquires, explores, develops, and produces mineral properties in the United States and Canada. The company has market cap of $272.78 million. It explores for gold and silver deposits. It currently has negative earnings. The firm holds 100% interests in the Fire Creek Property covering approximately 17,000 acres located in Lander County; the Midas mine and mill covering approximately 30,000 acres located in Elko County; and the True North gold mine and mill in Manitoba, Canada.
Among 6 analysts covering Voyager Therapeutics (NASDAQ:VYGR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Voyager Therapeutics had 7 analyst reports since December 7, 2015 according to SRatingsIntel. Chardan Capital Markets upgraded Voyager Therapeutics, Inc. (NASDAQ:VYGR) rating on Monday, January 25. Chardan Capital Markets has “Neutral” rating and $15 target. Chardan Capital Markets initiated Voyager Therapeutics, Inc. (NASDAQ:VYGR) rating on Wednesday, December 9. Chardan Capital Markets has “Sell” rating and $20 target. The rating was initiated by Wells Fargo with “Outperform” on Friday, May 20. The stock of Voyager Therapeutics, Inc. (NASDAQ:VYGR) has “Outperform” rating given on Monday, December 7 by Wedbush. Piper Jaffray initiated the shares of VYGR in report on Monday, December 7 with “Overweight” rating. Stifel Nicolaus initiated Voyager Therapeutics, Inc. (NASDAQ:VYGR) rating on Friday, July 15. Stifel Nicolaus has “Buy” rating and $33 target. The firm has “Outperform” rating given on Monday, December 7 by Cowen & Co.
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company has market cap of $608.86 million. The company's lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. It currently has negative earnings. The Company’s preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, Alzheimer's disease; and VY-NAV01 for severe chronic pain.